How India Exports Tacrolimus to the World

In the United States, tacrolimus is approved for preventing organ rejection in liver, kidney, and heart transplant recipients. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for tacrolimus, indicating a competitive generic market. Notably, the original New Drug Application (NDA) for Prograf (tacrolimus) injection was approved on April 8, 1994. As of March 2026, there are no active FDA import alerts specifically targeting tacrolimus products from India, suggesting compliance with U.S. regulatory standards. The substantial number of Indian exporters (299) underscores India's significant role in supplying tacrolimus to the U.S. market.

In the European Union, tacrolimus is authorized for preventing transplant rejection. The European Medicines Agency (EMA) granted marketing authorization for Advagraf (tacrolimus) on February 12, 2025. (ema.europa.eu) Additionally, the EMA has provided product-specific bioequivalence guidance for tacrolimus granules, effective November 1, 2016, to ensure consistent quality and efficacy among generic formulations. (ema.europa.eu) In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring compliance with EU Good Manufacturing Practice (GMP) guidelines for tacrolimus manufacturing.

Tacrolimus is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in healthcare systems worldwide. The drug is subject to international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, tacrolimus is classified as a Schedule H drug under the Drugs and Cosmetics Act, necessitating a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on tacrolimus, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products; however, tacrolimus is generally exempt from this requirement, facilitating its export.

The primary patents for tacrolimus have expired, leading to increased generic competition globally. This has resulted in a diversified market with multiple manufacturers producing generic versions, contributing to the drug's widespread availability and competitive pricing.

In May 2025, the EMA updated the product information for Advagraf, reflecting new safety data and usage guidelines. (ema.europa.eu) In August 2025, the EMA adopted a risk management plan summary for Tacforius, a generic tacrolimus product, to ensure its safe and effective use. (ema.europa.eu) In December 2025, the EMA updated the product information for Protopic, a tacrolimus ointment, to include new safety warnings. (ema.europa.eu) In February 2025, the EMA completed a periodic safety update report for Advagraf, ensuring ongoing monitoring of its safety profile. (ema.europa.eu) In May 2025, the EMA updated the product information for Tacforius, reflecting new safety data and usage guidelines. (ema.europa.eu)

These developments highlight the dynamic regulatory environment surrounding tacrolimus, emphasizing the importance of continuous monitoring and compliance with international standards to ensure patient safety and therapeutic efficacy.

India's pharmaceutical industry, including the production of Tacrolimus, heavily relies on importing Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) from China. This dependency is significant, with approximately 70% of APIs and KSMs being sourced from China. Such reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored these risks. For instance, in July 2018, environmental regulations in China led to the shutdown of numerous chemical factories, causing a substantial increase in the prices of KSMs and APIs. This event highlighted the fragility of the supply chain and the potential for sudden cost escalations and supply shortages.

Our proprietary trade data indicates a high concentration among Indian exporters of Tacrolimus. The top five exporters account for 80.2% of total exports, with SANDOZ PRIVATE LIMITED alone contributing 38.2%. Such concentration poses a significant risk, as disruptions affecting these key suppliers could severely impact the global supply of Tacrolimus.

To mitigate these risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing of APIs and reducing import dependence. As of November 2025, the scheme has led to the establishment of 26 APIs/KSMs/DIs with domestic production capability, resulting in sales of INR 23.15 billion and import savings of INR 18.07 billion.

Global shipping routes critical to the export of pharmaceuticals, such as the Red Sea and the Strait of Hormuz, have experienced disruptions due to geopolitical tensions. These disruptions can lead to delays and increased shipping costs, affecting the timely delivery of Tacrolimus to international markets.

Additionally, trade tensions between the United States and China have prompted regulatory bodies like the FDA to issue alerts regarding potential drug shortages. Such alerts emphasize the need for diversified sourcing strategies to ensure a stable supply of essential medications.

• Diversify Supplier Base: Encourage the development of alternative suppliers within India and other countries to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Support initiatives like the PLI scheme to strengthen domestic manufacturing capabilities for APIs and KSMs, thereby decreasing import dependence.

• Strengthen Regulatory Compliance: Ensure that suppliers adhere to international quality standards to mitigate risks associated with regulatory non-compliance.

• Develop Contingency Plans: Establish robust contingency plans to address potential disruptions in shipping routes and geopolitical tensions.

• Monitor Market Dynamics: Continuously monitor global market trends and regulatory changes to proactively address emerging risks in the supply chain.

RISK_LEVEL: MEDIUM